Strategic collaborations provide expanded
opportunities to apply PTC's scientific approach to additional therapeutic areas, access to development and
commercialization capabilities and significant financial resources.
|
Cystic Fibrosis Foundation — A grant for up to $25 million in support of key Phase 2b clinical trials for ataluren (PTC124™) in nonsense mutation cystic fibrosis.
|
|
Genzyme Corporation — PTC has an exclusive collaboration with Genzyme Corporation for the development and commercialization of ataluren. PTC Therapeutics will market ataluren in the United States and Canada, while Genzyme will commercialize the product in other regions of the world.
|
 |
Gilead — Exclusive research collaboration and licensing arrangement for the development of orally bioavailable small molecules through the application of PTC's proprietary GEMS (Gene Expression Modulation by Small-molecules) technology.
|
|
Muscular Dystrophy Association (MDA)—
Two grants totaling $2.5 million to support the development of ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy.
|
|
Merck & Co., Inc. (Schering-Plough Corporation) — $200 million collaboration for the development and commercialization of the compounds in the hepatitis C program.
|
|
Parent Project Muscular Dystrophy (PPMD) — Support for preclinical development of ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy (DMD) and a collaboration to discover new drugs to treat DMD called Project Catalyst.
|
|
Pfizer Inc. - An exclusive research collaboration and licensing agreement for the development of pharmaceuticals through the application of PTC’s GEMS (Gene Expression Modulation by Small-molecules) technology.
|
|
Spinal Muscular Atrophy Foundation — $11.7 million in grant funding to support discovery of new treatments for spinal muscular atrophy.
|